A STUDY TO EVALUATE THE CLINICAL EFFICACY OF JNJ-42756493 (ERDAFITINIB), A PAN-FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) TYROSINE KINASE INHIBITOR, IN ASIAN PARTICIPANTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER, UROTHELIAL CANCER, ESOPHAGEAL CANCER OR CHOLANGIOCARCINOMA: